RecruitingPhase 2NCT05039619
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
Studying Pediatric systemic lupus erythematosus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hoffmann-La Roche
- Principal Investigator
- Clinical TrialsHoffmann-La Roche
- Intervention
- Obinutuzumab(drug)
- Enrollment
- 40 target
- Eligibility
- 5-17 years · All sexes
- Timeline
- 2022 – 2030
Study locations (30)
- Loma Linda University health, Loma Linda, California, United States
- UCSF Benioff Childrens Hospital, San Francisco, California, United States
- Children's Hospital Colorado, Anchutz Medical Campus, Aurora, Colorado, United States
- Emory Children's Center, Atlanta, Georgia, United States
- Indiana University Health University Hospital, Indianapolis, Indiana, United States
- Louisiana State University, Shreveport, Louisiana, United States
- Hackensack University Medical Center, Hackensack, New Jersey, United States
- Cohen Children's Medical Center of New York, Queens, New York, United States
- Cincinnati Childrens Hospital, Cincinnati, Ohio, United States
- Chldren?s Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Texas Arthritis Center, El Paso, Texas, United States
- Ser Servicos Especializados Em Reumatologia, Salvador, Estado de Bahia, Brazil
- Centro de Pesquisa São Lucas, Campinas, São Paulo, Brazil
- Hospital das Clinicas - FMUSP, São Paulo, São Paulo, Brazil
- Universidade Federal de Sao Paulo - UNIFES, São Paulo, Brazil
- +15 more locations on ClinicalTrials.gov
Collaborators
Genentech, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05039619 on ClinicalTrials.govOther trials for Pediatric systemic lupus erythematosus
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07425730Early Myocardial Dysfunction Helps Identify Severe Refractory Pediatric LupusShanghai Jiao Tong University School of Medicine
- RECRUITINGNCT07128966Direct to Patient Minimal Risk Biospecimen and Data Collection ResearchJoined Bio
- RECRUITINGPHASE2NCT05538208The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) StudyChildren's Hospital Medical Center, Cincinnati
- RECRUITINGPHASE3NCT05835310An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric ParticipantsAstraZeneca
- RECRUITINGNANCT06586710Interferon Pathway Activation in Monogenic and Nonmonogenic Forms of Pediatric SLEMeyer Children's Hospital IRCCS
- ACTIVE NOT RECRUITINGPHASE2NCT04179032Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE)GlaxoSmithKline